NCT06307574 bpMedManage: Digital Technology to Support Adherence to Hypertension Medications
| NCT ID | NCT06307574 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Arizona |
| Condition | Aging |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-02-29 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-02-29 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the bpMedManage study is to rigorously test the efficacy of a smartphone technology to help improve high blood pressure medication adherence among older adults with mild cognitive impairment (MCI) in a 16-week randomized controlled trial. A total of 100 older adults will be recruited. There will be two treatment arms, bpMedManage-S and bpMedManage-P with 50 participants in each arm. Participants randomized into the bpMEDManage-S intervention arm will use a smartphone application with medication reminders plus receive education with standardized information on hypertension and antihypertensive medications on the education portal. Participants in the bpMedManage-P group will use a smartphone to receive education with standardized information on hypertension and antihypertensive medications on an education portal. Both groups will complete baseline assessments followed by 4 weeks of medication adherence monitoring. At the end of the adherence monitoring period, participants will be randomized into one of the two treatment arms. Immediate outcomes on primary and secondary measures will be assessed 4 weeks after beginning of the intervention. Follow-up outcomes will be assessed 12 weeks after the beginning of the intervention.
Eligibility Criteria
Inclusion Criteria: 1. Age 60+ 2. Community-dwelling older adults 3. Self-reported fluent in English 4. Adequate self-reported visual and hearing ability 5. Self-reported memory, thinking, or concentration challenges 6. Self-manage at least one prescribed antihypertensive medication 7. Have and use a smartphone 8. No self-reported history of major depression or other mental health diagnoses 9. No self-reported diagnosis of dementia or other neurological disorder such as stroke, TBI, and Parkinson's disease 10. TICS-M score between 27-37 and Montreal Cognitive Assessment (MoCA) score between 20-26 11. Willing to participate in the study for at least 4 months Exclusion Criteria: 1. Diagnosis of dementia 2. Lives in assisted living facility or skilled nursing facility
Contact & Investigator
Kathleen Insel, PhD
PRINCIPAL INVESTIGATOR
University of Arizona
Frequently Asked Questions
Who can join the NCT06307574 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06307574 currently recruiting?
Yes, NCT06307574 is actively recruiting participants. Contact the research team at insel@arizona.edu for enrollment information.
Where is the NCT06307574 trial being conducted?
This trial is being conducted at Tucson, United States, Champaign, United States.
Who is sponsoring the NCT06307574 clinical trial?
NCT06307574 is sponsored by University of Arizona. The principal investigator is Kathleen Insel, PhD at University of Arizona. The trial plans to enroll 100 participants.